Gilead Sciences (GILD) Expected to Post Earnings on Thursday

Gilead Sciences (NASDAQ:GILD) is anticipated to announce its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Gilead Sciences to post earnings of $2.18 per share and revenue of $7.81 billion for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 EPS. On average, analysts expect Gilead Sciences to post ($0.48) EPS for the current fiscal year and $9.94 EPS for the next fiscal year.

Gilead Sciences Stock Performance

GILD stock opened at $158.69 on Tuesday. Gilead Sciences has a one year low of $114.02 and a one year high of $160.51. The firm’s 50 day moving average price is $148.84 and its 200-day moving average price is $138.77. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total value of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. The trade was a 1.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director owned 12,894 shares in the company, valued at $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 111,000 shares of company stock worth $15,877,860 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: An analyst raised the fiscal 2026 EPS forecast for Gilead, signaling improved expectations for the company’s earnings outlook. FY2026 EPS Forecast for Gilead Sciences Raised by Analyst
• Positive Sentiment: Gilead’s latest deal highlights pharmaceutical-industry interest in oral peptide medicines. The transaction may support investor optimism about Gilead’s business-development strategy and longer-term growth opportunities in this emerging market. Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides
• Neutral Sentiment: Investors are preparing for Gilead’s third-quarter 2026 earnings report. Analysts are focused not only on revenue and EPS but also on operating metrics that could provide clues about product performance and the company’s outlook. Ahead of Gilead Q3 Earnings
• Neutral Sentiment: Recent coverage compares Gilead with Amgen as a dividend investment. Gilead offers a forward dividend yield above 2% and a lower payout ratio, although Amgen is reported to have stronger sales growth. Amgen vs. Gilead Sciences
• Negative Sentiment: The reported October short-interest data lists short interest at zero shares and a zero-day short-interest ratio despite describing a large increase. This apparent inconsistency limits its usefulness as a reliable signal of bearish positioning.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GILD. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. HSBC lifted their target price on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $160.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $159.81.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.